Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic

Cell Reports

Volumn 14, Issue 6, 2016, Pages 1477-1487

  Levine, Benjamin D ^a   Cagan, Ross L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drosophila; Fluvastatin; Non small cell lung cancer; Trachea; Trametinib

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN; TRAMETINIB; ANTINEOPLASTIC AGENT; DROSOPHILA PROTEIN; DRUG COMBINATION; INDOLE DERIVATIVE; INOSINATE DEHYDROGENASE; MONOUNSATURATED FATTY ACID; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, DROSOPHILA; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RASPBERRY PROTEIN, DROSOPHILA;

A549 CELL LINE; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; ENZYME INHIBITION; FRUIT FLY MODEL; GENE SILENCING; HUMAN; HUMAN CELL; LETHALITY; LUNG CANCER; MOLECULAR LIBRARY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PRENYLATION; THERAPEUTIC INDEX; TRACHEA; TRANSFORMED CELL; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DROSOPHILA MELANOGASTER; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMP DEHYDROGENASE; INDOLES; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; PYRIDONES; PYRIMIDINONES; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84958639001     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.12.105     Document Type: Article

References (43)

1. Andrew D.J., Ewald A.J. Morphogenesis of epithelial tubes: Insights into tube formation, elongation, and elaboration. Dev. Biol. 2010, 341:34-55.
2. Behr M. Molecular aspects of respiratory and vascular tube development. Respir. Physiol. Neurobiol. 2010, 173(August, Suppl):S33-S36.
3. Bellusci S., Furuta Y., Rush M.G., Henderson R., Winnier G., Hogan B.L. Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development 1997, 124:53-63.
4. Cabernard C., Affolter M. Distinct roles for two receptor tyrosine kinases in epithelial branching morphogenesis in Drosophila. Dev. Cell 2005, 9:831-842.
5. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
6. Carracedo A., Baselga J., Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008, 7:3805-3809.
7. Chen J., Bi H., Hou J., Zhang X., Zhang C., Yue L., Wen X., Liu D., Shi H., Yuan J., et al. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death Dis. 2013, 4:e814.
8. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
9. Chou T.-C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
10. Chu G., Jia R., Yang D. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway. J. Nephrol. 2006, 19:286-295.
11. Cook M., Mani P., Wentzell J.S., Kretzschmar D. Increased RhoA prenylation in the loechrig (loe) mutant leads to progressive neurodegeneration. PLoS ONE 2012, 7:e44440.
12. Denes A.S., Kanca O., Affolter M. A cellular process that includes asymmetric cytokinesis remodels the dorsal tracheal branches in Drosophila larvae. Development 2015, 142:1794-1805.
13. Djabrayan N.J.-V., Cruz J., de Miguel C., Franch-Marro X., Casanova J. Specification of differentiated adult progenitors via inhibition of endocycle entry in the Drosophila trachea. Cell Rep. 2014, 9:859-865.
14. Edgar B.A., Orr-Weaver T.L. Endoreplication cell cycles: more for less. Cell 2001, 105:297-306.
15. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., García-Echeverría C., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:19503-19508.
16. Guha A., Kornberg T.B. Tracheal branch repopulation precedes induction of the Drosophila dorsal air sac primordium. Dev. Biol. 2005, 287:192-200.
17. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., Januario T., Savage H., Punnoose E., Truong T., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009, 15:4649-4664.
18. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
19. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
20. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6:541-555.
21. Li S., De Souza P. Ras isoprenylation and pAkt inhibition by zoledronic acid and fluvastatin enhances paclitaxel activity in T24 bladder cancer cells. Cancers (Basel) 2011, 3:662-674.
22. Makino S. A morphological study of the nucleus in various kinds of somatic cells of Drosophila virilis. Cytologia 1938, 9:272-282.
23. Makino S., Niiyama H., Asana J.J. On the supernumerary chromosomes in the mole-cricket Gryllotalpa africana de BEAUVOIS from India (peliminary report). Jpn. J. Genet. 1938, 14:272-277.
24. Miraglia E., Högberg J., Stenius U. Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int. J. Oncol. 2012, 40:867-875.
25. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69:565-572.
26. Mistafa O., Stenius U. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem. Pharmacol. 2009, 78:1115-1126.
27. Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 2004, 229:567-585.
28. Mohammed A., Qian L., Janakiram N.B., Lightfoot S., Steele V.E., Rao C.V. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int. J. Cancer 2012, 131:1951-1962.
29. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
30. Park W.Y., Miranda B., Lebeche D., Hashimoto G., Cardoso W.V. FGF-10 is a chemotactic factor for distal epithelial buds during lung development. Dev. Biol. 1998, 201:125-134.
31. Park Y.H., Jung H.H., Ahn J.S., Im Y.-H. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem. Biophys. Res. Commun. 2013, 439:275-279.
32. Roeder T., Isermann K., Kallsen K., Uliczka K., Wagner C. A Drosophila asthma model - what the fly tells us about inflammatory diseases of the lung. Adv. Exp. Med. Biol. 2012, 710:37-47.
33. Santos A.C., Lehmann R. Isoprenoids control germ cell migration downstream of HMGCoA reductase. Dev. Cell 2004, 6:283-293.
34. Sato M., Kornberg T.B. FGF is an essential mitogen and chemoattractant for the air sacs of the drosophila tracheal system. Dev. Cell 2002, 3:195-207.
35. Shiga Y., Tanaka-Matakatsu M., Hayashi S. A nuclear GFP/β-galactosidase fusion protein as a marker for morphogenesis in living Drosophila. Dev. Growth Differ. 1996, 38:99-106.
36. Slack C., Alic N., Foley A., Cabecinha M., Hoddinott M.P., Partridge L. The Ras-Erk-ETS-signaling pathway is a drug target for longevity. Cell 2015, 162:72-83.
37. Son B.-K., Kozaki K., Iijima K., Eto M., Nakano T., Akishita M., Ouchi Y. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur. J. Pharmacol. 2007, 556:1-8.
38. Stinchcombe T.E., Johnson G.L. MEK inhibition in non-small cell lung cancer. Lung Cancer 2014, 86:121-125.
39. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
40. Weaver M., Krasnow M.A. Dual origin of tissue-specific progenitor cells in Drosophila tracheal remodeling. Science 2008, 321:1496-1499.
41. Wong W.W.L., Dimitroulakos J., Minden M.D., Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16:508-519.
42. Yin V.P., Thummel C.S. Mechanisms of steroid-triggered programmed cell death in Drosophila. Semin. Cell Dev. Biol. 2005, 16:237-243.
43. Yoon Y.-K., Kim H.-P., Han S.-W., Hur H.-S., Oh Y., Im S.-A., Bang Y.-J., Kim T.-Y. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009, 8:2526-2536.